Heart Failure POC and LOC Devices Market Analysis

Heart Failure POC and LOC Devices Market Analysis

To get key market trends

  Download Free Sample

Based on test type, the market is segmented into proteomic testing, metabolomic testing, and genomic testing. The proteomic testing segment is estimated to account for USD 155.9 million by the end of 2032.
 

• Proteomic testing enables comprehensive molecular profiling of proteins, peptides, and biomolecules present in biological samples such as blood, serum, plasma, or urine. By analyzing the protein composition and expression patterns, proteomic testing can identify disease-specific biomarkers, protein signatures, and molecular pathways associated with heart failure, cardiac remodeling, and myocardial dysfunction.
   
• It plays a crucial role in biomarker discovery and validation for heart failure and CVD. By comparing protein profiles between healthy individuals and patients with heart failure, proteomic assays can identify novel biomarkers indicative of disease onset, progression, severity, and prognosis.
   
• Proteomics testing enables early diagnosis and risk stratification of individuals at risk of developing heart failure or experiencing cardiovascular events. Consequently, detecting subtle changes in protein expression or post-translational modifications, proteomic assays can identify high-risk patients, predict adverse outcomes, and guide preventive interventions to mitigate disease progression and complications.
   
• Moreover, advances in proteomic technologies including mass spectrometry, immunoassays, protein microarrays, and multiplexed detection platforms, have enhanced the sensitivity, specificity, and throughput of proteomic testing for heart failure and CVD, thereby accelerating the segmental growth.
   

Based on technology, the heart failure POC and LOC devices market is divided into microfluidics, array-based systems, and other technologies. The microfluidics segment accounted for USD 43.7 million in 2023.
 

• Microfluidic-based devices are characterized by their small size, portability, and integration of multiple functions onto a single chip or platform. These compact devices enable point-of-care testing (POCT) and low-oxygen concentration (LOC) therapy to be performed at the patient's bedside, in ambulatory settings, or even at home, providing rapid results and immediate interventions for heart failure management.
   
• These devices utilize microscale channels, valves, pumps, and reaction chambers to manipulate small volumes of fluids, samples, and reagents with precise control and accuracy.
   
• Further, by reducing sample volume requirements, microfluidic-based assays minimize sample handling, processing time, and assay costs, making them well-suited for POC testing and rapid diagnostics in heart failure and cardiovascular diseases (CVD).
   
• Microfluidic-based systems offer automation and integration of sample preparation, assay execution, and data analysis steps within a single device or platform. These integrated systems streamline workflow, minimize user intervention, and reduce the risk of errors or contamination associated with manual sample handling.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on end-use, the heart failure POC and LOC devices market is divided into hospitals, specialty clinics, assisted living healthcare facilities, homecare settings, and other end-users. The hospitals segment accounted for a market share of 35.9% in 2023.
 

• Hospitals serve as centralized care settings where patients with heart failure and cardiovascular diseases (CVD) receive comprehensive medical care, including diagnosis, treatment, monitoring, and management of their condition. Consequently, they are primary locations for deploying POC and LOC devices for cardiac assessment, hemodynamic monitoring, and oxygen therapy.
   
• Hospitals are equipped with emergency departments, intensive care units (ICUs), cardiac catheterization labs, and specialized cardiac care units where POC and LOC devices are used for rapid assessment, triage, and initiation of therapeutic interventions to stabilize patients and prevent adverse outcomes.
   
• Further, many hospitals have specialized cardiac units or heart failure clinics dedicated to the management of patients with heart failure and CVD. These units provide multidisciplinary care by cardiologists, cardiac nurses, pharmacists, and other healthcare professionals who utilize POC and LOC devices for rapid diagnostics and risk stratification.
   
• These settings perform a wide range of diagnostic tests and monitoring procedures for heart failure patients. For instance, POC devices for cardiac biomarkers (e.g., troponin, BNP) and LOC devices for oxygen therapy are integral to the diagnostic workup and monitoring of heart failure patients in hospital settings, thus escalating the segmental growth.
   

The U.S. heart failure POC and LOC devices market is anticipated to grow at CAGR of 16% during the analysis time.
 

• The U.S. has a significant burden of heart failure and CVD, with millions of individuals affected by these conditions. For instance, according to the Heart Failure Society of America (HFSA), in 2023, about 6.2 million adults in the U.S. have heart failure.
   
• Further, factors such as aging population, sedentary lifestyles, unhealthy diets, and comorbidities contribute to the high prevalence of heart failure in the U.S.
   

Germany heart failure POC and LOC devices market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The country is known for its advanced healthcare system, which includes a network of hospitals, clinics, and healthcare facilities equipped with state-of-the-art medical technologies and devices.
   
• These facilities provide comprehensive medical care, including diagnosis, treatment, and management of heart failure and cardiovascular diseases (CVD), driving the demand for POC and LOC devices in the country.
   

Japan heart failure POC and LOC devices market is expected to grow significantly over the years.
 

• Japan has a growing focus on personalized medicine and remote monitoring solutions for chronic diseases such as heart failure. POC and LOC devices equipped with telehealth capabilities enable remote monitoring of heart failure patients, virtual consultations with healthcare providers, and real-time data transmission for timely interventions and care coordination, enhancing patient engagement and adherence to treatment plans.
   
• The country has been an early adopter of point-of-care testing (POCT) technologies for various medical applications, including cardiac biomarker testing, hemodynamic monitoring, and oxygen therapy.
   

UAE heart failure POC and LOC devices market is anticipated to witness lucrative growth between 2024 – 2032.
 

• UAE has been investing significantly in building and expanding its healthcare infrastructure to meet the needs of its growing population. The country boasts modern hospitals, clinics, and healthcare facilities equipped with state-of-the-art medical technologies and devices, including POC and LOC devices for heart failure management.
   
• It has emerged as a leading destination for medical tourism in the Middle East region, attracting patients from neighboring countries and around the world seeking specialized medical care and advanced treatment options. The availability of cutting-edge medical technologies, including POC and LOC devices, in UAE healthcare facilities contributes to the country's market share in heart failure management.